Inside Beta Bionics’ Blowout Quarter—and What’s Next for Modular Medical -( $BBNX $MODD )

Beta Bionics, Inc. (Nasdaq: BBNX), a leader in advanced diabetes management, delivered third-quarter results that energized expectations for both its growth trajectory and the sector at large. The company recorded net sales of $27.3 million, marking a robust 63% year-over-year increase and handily beating consensus analyst forecasts. Fueled by a 45% surge in Durable Medical Equipment (DME) channel sales and a remarkable 178% rise in Pharmacy Benefit Plan channel sales, Beta Bionics also expanded its installed user base to over 29,000, a jump of 162% from the previous year.

Financial Highlights and Market Impact

Gross margin climbed to 55.5%, up 212 basis points, driven by higher volumes and favorable product mix. Loss from operations narrowed compared to the prior year, and cash reserves remained solid at $274 million at quarter-end, providing firepower for continued innovation. Management responded to strong adoption of its iLet platform—particularly among multiple daily injection (MDI) users—with a confident upward revision of full-year 2025 revenue guidance to over $96.5 million. Recent clinical milestones, such as completion of a glucagon PK/PD trial and new regulatory filings, affirm Beta Bionics’ drive for next-generation, fully autonomous diabetes technology.

Competitive Landscape: The Modular Medical Push

As Beta Bionics accelerates its revenue and technology, Modular Medical (Nasdaq: MODD) is also making noteworthy progress in the insulin delivery space. Modular Medical recently completed Stage 1 of its ISO 13485:2016 audit with no major nonconformances, a critical milestone toward CE Mark certification for its Pivot insulin pump system in Europe. Preparations are underway for the final Stage 2 audit and a technical documentation review set for 2026, positioning Modular Medical for eventual commercial rollout in the EU.

Meanwhile, in the U.S., the Pivot platform aims to capitalize on the $3 billion “almost-pumpers” adult diabetes market, leveraging insights from usability and extended-wear feasibility studies, with a 510(k) FDA submission anticipated before year-end. Modular Medical’s next-gen tubeless, patch-based pump, which builds on the FDA-cleared MODD1 device, aspires to set new standards for simplicity, affordability, and accessibility.

Industry Outlook

With Beta Bionics’ momentum in sales, customer acquisition, and regulatory advances, and Modular Medical’s (Nasdaq: MODD) steady progress toward European and U.S. commercialization, the diabetes device market is signaling a new era of innovation and patient-centered solutions. Investors and clinicians alike should watch closely as both firms continue to push technological boundaries and reshape standards in chronic disease management.

​The Sources…

1. https://www.tipranks.com/news/company-announcements/beta-bionics-reports-strong-q3-growth-and-raises-guidance
2. https://seekingalpha.com/news/4509914-beta-bionics-raises-2025-revenue-guidance-to-96_5m-and-projects-q4-gross-margin-improvement
3. https://www.stocktitan.net/news/BBNX/beta-bionics-reports-third-quarter-2025-financial-results-and-raises-ykq9t251waah.html
4. https://www.biospace.com/press-releases/beta-bionics-reports-third-quarter-2025-financial-results-and-raises-full-year-2025-guidance
5. https://www.chartmill.com/news/BBNX/Chartmill-36147-Beta-Bionics-Inc-NASDAQBBNX-Tops-Q3-2025-Revenue-Estimates-and-Raises-Full-Year-Guidance
6. https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/35762723/beta-bionics-bbnx-q3-2025-earnings-transcript/
7. https://www.stocktitan.net/news/MODD/modular-medical-announces-ongoing-progress-to-obtain-ce-wiwmvx3rr4j3.html
8. https://finance.yahoo.com/news/modular-medical-announces-ongoing-progress-123000883.html
9. https://www.stocktitan.net/news/MODD/
10. https://www.biospace.com/press-releases/modular-medical-receives-irb-approval-for-pivot-insulin-delivery-system-feasibility-study
11. https://finance.yahoo.com/news/beta-bionics-inc-bbnx-reports-223003170.html
12. https://www.drugdeliverybusiness.com/beta-bionics-stock-rises-q3-2025/
13. https://finance.yahoo.com/news/beta-bionics-reports-third-quarter-200200715.html
14. https://www.gurufocus.com/news/3165574/beta-bionics-inc-bbnx-q3-2025-earnings-eps-loss-of-033-beats-estimate-revenue-surges-to-273-million
15. https://www.nasdaq.com/articles/beta-bionics-inc-bbnx-reports-q3-earnings-what-key-metrics-have-say
16. https://www.drugdeliverybusiness.com/modular-medical-new-head-international-operations/
17. https://ir.modular-medical.com
18. https://www.massdevice.com/modular-medical-begin-next-gen-insulin-pump-production/
19. https://public.com/stocks/modd/news/3